Pathogenesis, clinical evaluation and treatment of neuropathic cancer pain

doi:10.3760/cma.j.issn.1673-422X.2015.12.017

Abstract

Abstract: Neuropathic cancer pain (NCP) arises from physical or chemical damage to peripheral or central neurons or in the neural conduction system. The mechanisms of NCP include pain directly related to tumor involvement, pain associated with chemotherapy, radiotherapy and surgery, neuropathic syndromes associated with paraneoplastic syndromes, inflammation and other factors. A detailed history and careful physical examination are important means of diagnosis of NCP. The clinical evaluation of NCP should use standardized pain assessment scale. Till now, the treatments of NCP include opioid combined with auxiliary analgesic drugs, interventional treatment and gene treatment. Deciding treatment strategies according to the pathogenesis of NCP, multidisciplinary collaboration, combined therapy with different analgesic drugs and technologies are the therapeutic directions for NCP.

Key words: Neoplasms, Neuralgia, Diagnosis, Therapy

Liu Weishuai, Shao Yuejuan, Wang Kun. Pathogenesis, clinical evaluation and treatment of neuropathic cancer pain[J]. Journal of International Oncology, 2015, 42(12): 946-949.

References

［1］ van den Beukenvan Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years［J］. Ann Oncol, 2007, 18(9): 1437-1449. ［2］Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review［J］. Pain, 2012, 153(2): 359-365. ［3］Neal AJ, Qian MY, Clinch AS, et al. Orthostatic hypotension secondary to CRMP5 paraneoplastic autonomic neuropathy［J］. J Clin Neurosci, 2014, 21(5): 885-886. ［4］GarzónRodríguez C, Lyras L, Gayoso LO, et al. Cancerrelated neuropathic pain in outpatient oncology clinics: a European survey［J］. BMC Palliat Care, 2013, 12(1): 41. ［5］Cheng KI, Wang HC, Chuang YT, et al. Persistent mechanical allodynia positively correlates with an increase in activated microglia and increased Pp38 mitogenactivated protein kinase activation in streptozotocininduced diabetic rats［J］. Eur J Pain, 2014, 18(2): 162-173. ［6］Delaney A, FleetwoodWalker SM, Colvin LA, et al. Translational medicine: cancer pain mechanisms and management［J］. Br J Anaesth, 2008, 101(1): 87-94. ［7］Yawn BP, Gilden D. The global epidemiology of herpes zoster［J］. Neurology, 2013, 81(10): 928-930. ［8］Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain［J］. Pain, 2007, 127(3): 199-203. ［9］Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision［J］. Eur J Neurol, 2010, 17(9): 1113-1188. ［10］ King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project［J］. Palliat Med, 2011, 25(5): 525-552. ［11］ Attal N. Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials［J］. Continuum (Minneap Minn), 2012, 18(1): 161-175. ［12］李小梅, 刘端祺, 吴航宇, 等. 羟考酮控释片单药或联合加巴喷丁治疗癌性神经病理性疼痛的临床研究［J］. 中国疼痛医学杂志, 2010, 16(5): 276-279. ［13］ Mishra S, Bhatnagar S, Gupta D, et al. Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study［J］. Am J Hosp Palliat Care, 2008, 25(6): 447-451. ［14］ Auret K, Schug SA. Pain management for the cancer patientcurrent practice and future developments［J］. Best Pract Res Clin Anaesthesiol, 2013, 27(4): 545-561. ［15］ Swarm RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain［J］. J Natl Compr Canc Netw, 2013, 11(8): 992-1022. ［16］丁亚文, 冯刚, 张丽娟, 等. 盐酸文拉法辛胶囊联合羟考酮缓释片治疗中重度癌痛的临床研究［J］. 华中科技大学学报: 医学版, 2012, 41(4): 485-489. ［17］ Eardley W, Toth C. An openlabel, nonrandomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy［J］. J Pain Res, 2010, 3: 33-49. ［18］ Fortes C, Farchi S, Forastiere F, et al. Depressive symptoms lead to impaired cellular immune response［J］. Psychother Psychosom, 2003, 72(5): 253-260. ［19］ Raptis E, Vadalouca A, Stavropoulou E, et al. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, headtohead, randomized, openlabel study［J］. Pain Pract, 2014, 14(1): 32-42. ［20］ Becker R, Jakob D, Uhle EI, et al. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions［J］. Stereotact Funct Neurosurg, 2000, 75(1): 16-26. ［21］ Saliou G, Kocheida el M, Lehmann P, et al. Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement［J］. Radiology, 2010, 254(3): 882-890. ［22］ Thanos L, Mylona S, Galani P, et al. Radiofrequency ablation of osseous metastases for the palliation of pain［J］. Skeletal Radiol, 2008, 37(3): 189-194. ［23］ Kage K, Niforatos W, Zhu CZ, et al. Alteration of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat［J］. Exp Brain Res, 2002, 147(4): 511-519. ［24］ Liu W, Liu Z, Liu L, et al. A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury［J］. Neurosci Lett, 2008, 432(1): 13-18. ［25］ Bali KK, Selvaraj D, Satagopam VP, et al. Genomewide identification and functional analyses of microRNA signatures associated with cancer pain［J］. EMBO Mol Med, 2013, 5(11): 1740-1758.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.